Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1103	2008/0145373	06-19-2008	Arumugham et al.	
	1096	2007/0021454 A1	01-25-2007	Coburn et al.	
	1099	2006/0057701 A1	03-16-2006	Rosenthal et al.	
	1098	2005/0090648 A1	04-28-2005	Tsurushita et al.	
	1101	2003/0054484 A1	03-20-2003	Fong et al.	
	1131	6,015,662	01-18-2000	Hackett et al.	
	1148	5,773,007	06-30-1998	Penney et al.	
	1147	5,723,130	03-03-1998	Hancock et al.	

U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1129	11/842,085	08-20-2007	Schenk	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (if known)				
	1102	EP	1 690 547	A1	08-16-1998			☐
	1135	WO	08/131298	A3	12-18-2008			☐
	1107	WO	08/131298	A2	10-30-2008			☐
	1133	WO	06/042158	A	04-20-2006			☐
	1146	WO	05/035753	A	04-21-2005			☐
	1145	WO	87/02671	A	05-07-1987			☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 5

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1120	ARMOUR et al., "Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activites," J. Immunol, 29:2613-2624 (1999).	☐
	1117	AVIS, "Perenteral Preparations," *Remington's Pharmaceutical Sciences*, 17:1518-1519 (1985).	☐
	1138	BRINKMAN, "Splice Variants as Cancer Biomarkers," Clinical Biochemisrty, 37(7):584-594 (2004).	☐
	1110	CHEN et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," J. Mol. Biol., 293:865-881 (1999).	☐
	1142	CHOI et al., "A Generic Intron Increases Gene Expression in Transgenic Mice," Molecular and Cellular Biology, 11(6):3070-3074 (1991).	☐
	1132	Corcoran et al., "Overexpression of hAPPswe Impaires Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease," Learn Mem. 9(5):243-252:2000.	☐
	1144	DATABASE Geneseq, "Nucleotide Sequence of a Variable Heavy Chain of IgG4," EBI Accession No. GSN:ADZ51216 (2005).	☐
	1100	Dialog/Derwent, Abstract of WPI Acc No: 1995-261292/199534: Novel monoclonal antibody against human high-affinity IgE receptor – and DNA fragment encoding the MAb, for the specific identification of human Fc-epsilon RI, Derwent WPI database (1995).	☐
	1137	Extended European Search Report of 12/18/08 for European Application 05812436.6-1212.	☐
	1136	European Examination Report of 09/23/2008 for European Application 04776252.1-2405.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	Kolker, Daniel E.
Sheet	3	of	5	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1130	European Examination Report as part of 12-08-2008 communication for European Application 04720353.4	☐
	1134	European Examination Report of 11/20/2008 for European Application 08011409.3	☐
	1150	Family and legal status of EP0613007, Inpadoc Search (2009).	☐
	1097	FRAGIONE et al., "Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid, 8(Suppl 1):36-42 (2001), abstract only.	☐
	1118	HEZAREH et al., "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," Journal of Virology, 24(75):12161-12168 (2001).	☐
	1127	JANEWAY et al., *Immunobiology*, 3rd eidition, pages 8:18-8:19 (1997).	☐
	1121	MANN et al., "Atypical Amyloid (ABeta) Deposition in the cerebellum in Alzheimer's Disease: An Immunohistochemical Study Using End-Specific ABeta Monoclonal Antibodies," ACTA Neuropathologica, 91:647-653 (1996).	☐
	1122	MANN et al., "Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutatuibs in the amyloid precursor protirn gene," The American Journal of Pathology APR, 4(148): 1257-1266 (1996).	☐
	1139	MYERS et. al., "Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 5T4-Specific SCFV Fusion Protiens," Cancer Gene Therapy, 9(11):884-896 (2002).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	Kolker, Daniel E.
Sheet	4	of	5	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1108	PASCALIS et al., "Grafting of "Abbreviated" Complementarity-Determining Containing Specifictiy-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," The Journanal Immunology, 169:3076-3084 (2002).	☐
	1149	QU et al., "$A\beta_{42}$ gene Vaccine Prevents $A\beta_{42}$ deposition in brain of Double Trangenic Mice," J. Neurological Sciences, 260:204-213 (2007).	☐
	1141	ROBBINS et al., "The Intronic Region of an Imcompletely Spliced gp100 Gene Transcript Encodes an Epitope Recognized by Melanoma-Reactive Tumor-Infiltrarting Lymphocytes," Journal of Immunology, 159(1):303-308 (1997).	☐
	1140	SEABROOK et al., "Species-specific Immune response to Immunization with Human Versus rodent Abeta Peptide," Neuobiology of Aging, 25(9) 1141-1151 (2004)	☐
	1123	SCHMIDT et al., "Monoclonal Antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains," The American Journal of Pathology, 1(151):69-80 (1997).	☐
	1119	Shepherd et al., "The design of the humanized antibody," Monocolonal Antibodies: A Pratical Approcach 58-66 (2000)	☐
	1104	SIDHU, "Page display in pharmaceutical biotechnology," Current Opinoin in Biotechnology, 11:610-616 (2000).	☐
	1105	SMITH et al., "Phage Display," Chemical Reviews, American Chemical Society, 97(2):391-410 (1997).	☐
	1128	STUDNICKA et al., "Human-engineered monocilnal antibodies retain full specific binding activity by preserving non-CDR complemenatary-modullating resudes," Protien Eng., 7(6):805-814 (1994), Abstract only.	☐
	1124	TAMAOKAet al., "Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehyrogenase (GAPDH)," Neurobiology of Aging, 3(17):405-414 (1996).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	Kolker, Daniel E.
Sheet	5	of	5	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1112	U.S. Application No. 09/316,387, Office Action mailed 09/10/2007.	☐
	1113	U.S. Application No. 09/316,387, Response to 06-20-2005 Office Action filed 12-20-2005.	☐
	1114	U.S. Application No. 09/316,387, Declaration of Solomon, Hrncic, and Wall under 37 C.F.R. § 1.131 filed 03-06-2006.	☐
	1115	U.S. Application No. 09/316,387, Office Action mailed 06/20/2005.	☐
	1109	Vajdos et al., "Comprehensive Functional Maps of the Antigen-binging site of an Anti_ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," J. Mol. Biol., 320:415-428 (2002).	☐
	1143	WARD et al., "Spontaneous Deletions In IG Heavy Chain Genes Flaking Seuences Influence Splice Site Selection Nucleic Acids Research," 19(23): 6475-6480 (1991).	☐
	1106	WILSON et al., "Phage display: applications, innovations, and issues in phage and host biology," Can. J. Microbiol, 44:313-329 (1998).	☐
	1111	WU et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," J. Mol. Biol., 294:151-162 (1999).	☐
	1125	YANAGISAWA K et al., "Amyloid BETA-protein (Alpha-Beta) associated with lipid molecules: immunoreactivity distinct from that of soluble Alpha-Beta," FEBS Letters, 1(420): 43-46 (1997).	☐
	1126	YANG et al., "Monoclonal Antibody to the C-terminus of Beta-Amyloid," Neuroreport, 16(5):2117-2120 (1994).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.